UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine

Seminars in oncology, 1999-04, Vol.26 (2 Suppl 7), p.3

Capizzi, R L

1999

Volltextzugriff (PDF)

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects

Seminars in oncology, 1999-04, Vol.26 (2 Suppl 7), p.72

Capizzi, R L

1999

Volltextzugriff (PDF)

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors

Leukemia, 1998-10, Vol.12 (10), p.1596-1602

1998

Volltextzugriff (PDF)

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity

Seminars in oncology, 1996-08, Vol.23 (4), p.58-63

1996

Volltextzugriff (PDF)

Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

European journal of cancer (1990), 1997-09, Vol.33 (10), p.1693-1698

1997

Volltextzugriff (PDF)

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)

European journal of cancer (1990), 1996, Vol.32, p.S5-S16

Capizzi, R.L.

1996

Volltextzugriff (PDF)

Cutaneous manifestations in celiac disease

World journal of gastroenterology : WJG, 2006-02, Vol.12 (6), p.843

2006

Volltextzugriff (PDF)

Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol) : clinical experiences

Seminars in oncology, 1994-10, Vol.21 (5), p.8-15

CAPIZZI, R. L

1994

Volltextzugriff (PDF)

Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences

European journal of cancer (1990), 1995, Vol.31, p.S8-S13

1995

Volltextzugriff (PDF)

The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer

Journal of clinical oncology, 1991-03, Vol.9 (3), p.371-380

1991

Volltextzugriff (PDF)

Amifostine improves the antileukemic therapeutic index of mafosfamide : implications for bone marrow purging

Blood, 1995-10, Vol.86 (7), p.2849-2855

1995

Volltextzugriff (PDF)

Chemoprotective and radioprotective effects of amifostine : An update of clinical trials

International journal of hematology, 2000-12, Vol.72 (4), p.425-435

2000

Volltextzugriff (PDF)

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies

Seminars in oncology, 1996-08, Vol.23 (4 Suppl 8), p.2

Capizzi, R

1996

Volltextzugriff (PDF)

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

The Journal of clinical investigation, 1987-02, Vol.79 (2), p.380-387

1987

Volltextzugriff (PDF)

Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

Cancer, 1993-12, Vol.72 (S11), p.3495-3501

1993

Volltextzugriff (PDF)

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse : Preliminary results

Seminars in oncology, 1996-08, Vol.23 (4), p.35-39

1996

Volltextzugriff (PDF)

Clinical status and optimal use of amifostine

Oncology (Williston Park, N.Y.), 1999-01, Vol.13 (1), p.47

Capizzi, R L

1999

Volltextzugriff (PDF)

Treatment of Poor Risk Acute Leukemia With Sequential High-Dose ARA-C and Asparaginase

Blood, 1984-03, Vol.63 (3), p.694-700

1984

Volltextzugriff (PDF)

Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer

Clinical cancer research, 1996-07, Vol.2 (7), p.1107-1114

1996

Volltextzugriff (PDF)

WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

European journal of cancer (1990), 1996, Vol.32, p.S17-S20

1996

Volltextzugriff (PDF)

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

Journal of clinical oncology, 1983-12, Vol.1 (12), p.763-771

1983

Volltextzugriff (PDF)

Recent Developments and Emerging Options: The Role of Amifostine as a Broad-Spectrum Cytoprotective Agent

Seminars in oncology, 1999-04, Vol.26 (2), p.1-2

CAPIZZI, Robert L

1999

Volltextzugriff (PDF)

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study

Journal of clinical oncology, 1988-03, Vol.6 (3), p.499-508

1988

Volltextzugriff (PDF)

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

Journal of clinical oncology, 1988-07, Vol.6 (7), p.1098-1106

1988

Volltextzugriff (PDF)

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

Stroke (1970), 1999-09, Vol.30 (9), p.1907-1915

1999

Volltextzugriff (PDF)

1 – 25 von 284

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(238)
Mit Volltextzugriff
(203)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(190)
Humans
(165)
Life Sciences & Biomedicine
(156)
Female
(97)
Male
(87)
Oncology
(86)
Biological And Medical Sciences
(80)
Medical Sciences
(76)
Middle Aged
(72)
Adult
(65)
Pharmacology. Drug Treatments
(56)
Animals
(50)
Aged
(46)
Antineoplastic Agents
(42)
Chemotherapy
(31)
Mice
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(28)
Cytarabine - Administration & Dosage
(25)
Child
(24)
Physical Sciences
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(21)
Seminars In Oncology
(18)
Cancer Research
(15)
Cancer
(10)
Cancer Treatment Reports
(8)
Blood
(7)
Cancer Chemotherapy And Pharmacology
(7)
European Journal Of Cancer
(7)
Investigational New Drugs
(7)
Leukemia
(7)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity

Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)

Cutaneous manifestations in celiac disease

Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol) : clinical experiences

Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences

The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer

Amifostine improves the antileukemic therapeutic index of mafosfamide : implications for bone marrow purging

Chemoprotective and radioprotective effects of amifostine : An update of clinical trials

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse : Preliminary results

Clinical status and optimal use of amifostine

Treatment of Poor Risk Acute Leukemia With Sequential High-Dose ARA-C and Asparaginase

Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer

WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

Recent Developments and Emerging Options: The Role of Amifostine as a Broad-Spectrum Cytoprotective Agent

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

Suchergebnisse filtern